Every material Form 8-K Kalaris Therapeutics, Inc. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kalaris Therapeutics reported a second-quarter 2026 net loss of $11.5 million, nearly flat from $11.4 million a year earlier, with no revenue line in the filing. Cash, cash equivalents and marketable securities fell to $93.5 million from $118.0 million at December 31, 2025, and the company says this is expected to fund operations into the fourth quarter of 2027.
Net loss per share was $0.48 for the quarter, versus $0.61 a year earlier, on a weighted-average share count of 23,797,306 compared with 18,701,286.
Research and development expenses rose to $9.0 million from $8.4 million, mainly from higher clinical costs for TH103 as more sites were opened and patients enrolled.
General and administrative expenses fell to $3.4 million from $3.8 million, mainly due to lower legal, accounting and professional fees.
Preliminary Phase 1b/2 data for TH103 is expected in the first half of 2027, and potential Phase 3 trials remain on track to start by year-end 2027.
Kalaris Therapeutics appointed Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, and she will also serve as principal financial officer. The company also disclosed that Chief Accounting Officer Brett Hagen is resigning effective July 27, 2026, and Corporate Controller Amy Vandekop will serve as interim principal accounting officer.
Liisa Bayko's annualized base salary is $475,000, with an annual target bonus of up to 40.0% of base salary.
Bayko received an incentive stock option to purchase up to 220,000 shares of common stock, vesting 25% on the first anniversary of the effective date and then in 36 monthly installments.
Bayko previously was Managing Director, Biotech Equity Research at Evercore ISI from August 2020 to December 2025.
Brett Hagen notified the company on July 14, 2026 of his resignation as SVP, Finance and Chief Accounting Officer, effective July 27, 2026.
Kalaris Therapeutics released additional data from the expanded Phase 1a single ascending dose trial of TH103 in treatment-naive patients with neovascular age-related macular degeneration, with 20 patients completing six months of follow-up. The results build on earlier reported findings on vision, retinal anatomy and time to retreatment, but the filing covers an early-stage trial with small cohorts and includes no financial figures. The company said its Phase 1b/2 study remains on track to share initial data in the first half of 2027.
Expanded dataset includes 17 treatment-naive patients and 3 treatment-experienced patients; all 20 completed six months of follow-up.
Mean 9.2-letter best corrected visual acuity improvement at one month after a single TH103 injection in treatment-naive patients.
41% of treatment-naive patients (N=17) received a first retreatment at four months or later; 29% received no additional anti-VEGF treatment during six months.
No intraocular inflammation among six patients at the 2.5 mg dose; one patient at the 5 mg dose had transient IOI that resolved without sequelae.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kalaris Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →